Study of IBI3016 in People With Mild or Moderate Hypertension Patients

Summary

A Phase I clinical study evaluating the safety, tolerability, pharmacokinetic characteristics, and pharmacodynamic characteristics of a single subcutaneous dose of IBI3016 in Chinese patients with mild to moderate hypertension.

Timeline

Start

2026-05-15

Primary completion

2027-10-16

Completion

2027-10-16

Drugs

Indications